KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Asset Writedowns and Impairment (2017 - 2024)

Bionano Genomics' Asset Writedowns and Impairment history spans 4 years, with the latest figure at $6.0 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $6.0 million; the TTM value through Dec 2024 reached $7.2 million, changed N/A, while the annual FY2024 figure was $7.2 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was $6.0 million at Bionano Genomics, up from $800000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $6.0 million in Q4 2024 and bottomed at $44000.0 in Q3 2020.
  • The 3-year median for Asset Writedowns and Impairment is $541000.0 (2020), against an average of $1.2 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 16.02% in 2020 against a maximum downside of 16.02% in 2020.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $466000.0 in 2020, then soared by 32.19% to $616000.0 in 2022, then soared by 866.23% to $6.0 million in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Asset Writedowns and Impairment are $6.0 million (Q4 2024), $800000.0 (Q3 2024), and $448000.0 (Q1 2024).